ZIOPHARM Oncology Inc - ESG Rating & Company Profile powered by AI
The webpage is a free Environmental, Social and Governance analysis for ZIOPHARM Oncology Inc. This ESG rating for ZIOPHARM Oncology Inc indicates its reporting of the UN Sustainable Development Goals. The ESG score covers 17 UN SDGs including: 'Good Health & Wellbeing', 'Sustainable Cities & Communities' and 'Life on Land'.
ZIOPHARM Oncology Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.7; made up of an environmental score of 6.0, social score of 1.6 and governance score of 6.4.
4.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 816 | Pliant Therapeutics Inc | 4.8 | High |
| 816 | Voyager Therapeutics Inc | 4.8 | High |
| 837 | ZIOPHARM Oncology Inc | 4.7 | High |
| 837 | Bio Rad Laboratories Inc | 4.7 | High |
| 837 | Katakura Industries Co Ltd | 4.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does ZIOPHARM Oncology Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc report the average age of the workforce?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose cybersecurity risks?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc offer flexible work?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc conduct supply chain audits?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes ZIOPHARM Oncology Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose water use targets?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid ZIOPHARM Oncology Inc have a product recall in the last two years?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose incidents of discrimination?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas ZIOPHARM Oncology Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose parental leave metrics?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs ZIOPHARM Oncology Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose its waste policy?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc report according to TCFD requirements?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose energy use targets?
Sign up for free to unlockDoes ZIOPHARM Oncology Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes ZIOPHARM Oncology Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for ZIOPHARM Oncology Inc
These potential risks are based on the size, segment and geographies of the company.
ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.